Download Files:

JNJ-38877618

SKU HY-111050-10 mg Category Reference compound Tags c-Met/HGFR, Cancer, Protein Tyrosine Kinase/RTK

$170 – $1,350

Size

Products Details

Product Description

– JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.

Web ID

– HY-111050

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C20H12F2N6

References

– [1]Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4791.

CAS Number

– 943540-74-7

Molecular Weight

– 374.35

Compound Purity

– 98.76

SMILES

– FC(C1=CC=C2N=CC=CC2=C1)(F)C3=NN=C4C=CC(C5=CC=NC=C5)=NN43

Clinical Information

– Phase 1

Research Area

– Cancer

Solubility

– DMSO : 5 mg/mL (ultrasonic)

Target

– c-Met/HGFR

Pathway

– Protein Tyrosine Kinase/RTK

Product type

– Reference compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.